KDx Diagnostics announces FDA Breakthrough Device designation for URO17(TM), Innovative urine test for Bladder Cancer
CAMPBELL, Calif., Jan. 8, 2020 /PRNewswire/ -- KDx Diagnostics, Inc. (KDx), announced today that the Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its URO17(TM) Bladder Cancer Recurrence Test. This revolutionary new test exploits a novel cancer marker that could dramatically improve the accuracy and sensitivity of non-invasive bladder cancer testing.
Bladder cancer is the 6(th) most common cancer in the US, and 81,000 people are newly diagnosed with the disease annually. Moreover, bladder cancer has a relatively high recurrence rate and is one of the most expensive patients to treat, in part because patients must be regularly monitored for recurrence.
KDx has published data (Babu et al., 2018) showing the URO17(TM) test exhibited 100% sensitivity and 96% specificity in detecting recurrent bladder cancer from urine samples. While this was an initial study, these rates are among the best ever reported for a non-invasive test.
"The FDA's designation of Breakthrough Device for our URO17 test validates our excitement about the potential of our test to improve bladder cancer treatment with attendant major impact in the marketplace for bladder cancer diagnostics. Breakthrough Device designation significantly enhances our ability to conduct the necessary clinical trials for approval and expedites the review process. We look forward to working closely with the FDA during this next exciting phase of product development," said Nam W. Kim, Ph.D., KDx' Co-Founder and CEO.
About KDx Diagnostics, Inc.
Founded in 2017, KDx is focused on developing non-invasive cancer tests to improve early detection and therapy decisions in cancer. The URO17(TM) bladder cancer test developed by KDx may prove to be the most sensitive and specific test for bladder cancer developed to date. KDx plans to develop tests based on the same biomarker for other platforms and sample types and expand its product line into other cancer diagnostic tests.
Contact:
Public Relations
KDx Diagnostics Inc.
408-628-7715
info@kdxdiagnostics.com
URO17 is a trademark of KDx.
Forward-Looking Statements
KDx cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," project," "target," "tend to," or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to planned clinical studies and meetings with regulatory agencies. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause KDx's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in KDx's business and other risks in KDx's filings with the Securities and Exchange Commission (the SEC). KDx's forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. KDx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View original content:http://www.prnewswire.com/news-releases/kdx-diagnostics-announces-fda-breakthrough-device-designation-for-uro17-innovative-urine-test-for-bladder-cancer-300984027.html
SOURCE KDx Diagnostics Inc.
